Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00647556 · ClinicalTrials.gov registry record · Phase 3

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

A Phase 3 study of Photoaging, sponsored by Galderma R&D.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target
1
Study location

NCT00647556 is a Phase 3 study of Photoaging that has completed, run by Galderma R&D. The registered enrollment target is 30 participants, roughly in line with the 30-participant average among 14 other Photoaging trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00647556, a Phase 3 study of Photoaging, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to compare the efficacy of adapalene (Differin®) gel 0.3% and tretinoin 0.05% emollient cream for the treatment of signs of photodamage, with tolerability assessment as a secondary objective.

Conditions Studied

Interventions

  • DRUG adapalene gel, 0.3%
  • DRUG tretinoin 0.05% emollient cream

Study Locations (1)

Michigan

  • University of Michigan Department of Dermatology - Ann Arbor

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-04
Est. Completion 2010-01
Phase Phase 3

Sponsor

Galderma R&D

158 total trials

What the Registry Record Tells You About NCT00647556

The ClinicalTrials.gov registry entry for NCT00647556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 30-participant average among 14 other Photoaging trials with a reported enrollment target. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Photoaging appearing as the primary indexed condition, and to 2 interventions - of which adapalene gel, 0.3% is the first listed.

NCT00647556 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT00647556 about?

NCT00647556 is a clinical study titled "Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage". The primary purpose of this study is to compare the efficacy of adapalene (Differin®) gel 0.3% and tretinoin 0.05% emollient cream for the treatment of signs of photodamage, with tolerability assessment as a secondary objective.

What is the current status of trial NCT00647556?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2008-04. Estimated completion is 2010-01.

What conditions does trial NCT00647556 study?

This clinical trial studies the following conditions: Photoaging.

What interventions are being tested in trial NCT00647556?

The interventions under investigation include: adapalene gel, 0.3% (DRUG), tretinoin 0.05% emollient cream (DRUG).

Who is sponsoring clinical trial NCT00647556?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00647556 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Photoaging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.